GPC Biotech AG (Frankfurt Stock Exchange: GPC; NASDAQ: GPCB) today
announced that it will hold a conference call on Wednesday, August 13,
2008 to discuss its financial results for the second quarter and first
half of 2008. The results will be published on August 13th in advance of
the call.
Participants may listen via live webcast, accessible through the GPC
Biotech Web site at www.gpc-biotech.com,
or via telephone. A replay will be available via the Web site following
the live event. The call, which will be conducted in English, will be
held on August 13 at 14:00 CET/8:00 AM ET.
The dial-in numbers for the call are as follows:
European participants: 0049 (0)89 9982 99911 or 0044 (0)20 7806 1955
U.S. participants: 1-718-354-1388
About GPC Biotech
GPC Biotech AG is a publicly traded biopharmaceutical company focused on
anticancer drugs. GPC Biotech's lead product candidate is satraplatin,
an oral platinum compound. The Company has various anti-cancer programs
in research and development that leverage its expertise in kinase
inhibitors. GPC Biotech AG is headquartered in Martinsried/Munich
(Germany) and has a wholly owned U.S. subsidiary in Princeton, New
Jersey. For additional information, please visit GPC Biotech's Web site
at www.gpc-biotech.com.
This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of GPC Biotech.
Such statements are based on current expectations and are subject to
risks and uncertainties, many of which are beyond our control, that
could cause future results, performance or achievements to differ
significantly from the results, performance or achievements expressed or
implied by such forward-looking statements. Actual results could differ
materially depending on a number of factors, and we caution investors
not to place undue reliance on the forward-looking statements contained
in this press release. We direct you to GPC Biotech’s
Annual Report on Form 20-F for the fiscal year ended December 31, 2007
and other reports filed with the U.S. Securities and Exchange Commission
for additional details on the important factors that may affect the
future results, performance and achievements of GPC Biotech.
Forward-looking statements speak only as of the date on which they are
made and GPC Biotech undertakes no obligation to update these
forward-looking statements, even if new information becomes available in
the future.
GPC Biotech AG
Investor Relations & Corporate Communications
+49
(0)89 8565-2693
ir@gpc-biotech.com
or
In
the U.S.:
Laurie Doyle, 609-524-5884
Director, Investor
Relations & Corporate Communications
usinvestors@gpc-biotech.com
or
Additional
media contacts for Europe:
MC Services AG
Raimund Gabriel,
+49 (0) 89 210 228 0
raimund.gabriel@mc-services.eu
or
Hilda
Juhasz, +49 (0) 89 210 228 0
hilda.juhasz@mc-services.eu
or
Additional
investor contact for Europe:
Trout International LLC
Lauren
Rigg, +44 207 936 9325
Vice President
lrigg@troutgroup.com
